{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:52:21Z","timestamp":1782993141543,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.jocn.2021.03.015","type":"journal-article","created":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T04:32:57Z","timestamp":1617337977000},"page":"70-74","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"88","author":[{"given":"Zheyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang'e","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingze","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianming","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"26","key":"10.1016\/j.jocn.2021.03.015_b0005","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Longo","year":"2016","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jocn.2021.03.015_b0010","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: Executive summary","volume":"87","author":"Sanders","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2021.03.015_b0015","doi-asserted-by":"crossref","unstructured":"Skeie, G.O., et al., Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol, 2010. 17(7): p. 893-902.","DOI":"10.1111\/j.1468-1331.2010.03019.x"},{"issue":"1","key":"10.1016\/j.jocn.2021.03.015_b0020","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"Gilhus","year":"2015","journal-title":"Eur J Neurol"},{"issue":"3","key":"10.1016\/j.jocn.2021.03.015_b0025","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2009.11.024","article-title":"Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease","volume":"8","author":"Long","year":"2010","journal-title":"Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association"},{"issue":"5","key":"10.1016\/j.jocn.2021.03.015_b0030","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1053\/j.gastro.2011.07.039","article-title":"Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease","volume":"141","author":"Singh","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jocn.2021.03.015_b0035","doi-asserted-by":"crossref","unstructured":"Setshedi, M., et al., Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. Journal of gastroenterology and hepatology, 2012. 27(2): p. 385-389.","DOI":"10.1111\/j.1440-1746.2011.06865.x"},{"issue":"4","key":"10.1016\/j.jocn.2021.03.015_b0040","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/gut.47.4.514","article-title":"Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low","volume":"47","author":"Farrell","year":"2000","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.jocn.2021.03.015_b0045","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1046\/j.1365-2036.2001.01125.x","article-title":"Review article: does the use of immunosuppressive therapy in inflammatory bowel disease increase the risk of developing lymphoma?","volume":"15","author":"Bebb","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.jocn.2021.03.015_b0050","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/gut.2004.049460","article-title":"Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine","volume":"54","author":"Kandiel","year":"2005","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jocn.2021.03.015_b0055","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdr333","article-title":"Autoimmune disease and subsequent digestive tract cancer by histology","volume":"23","author":"Hemminki","year":"2012","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.jocn.2021.03.015_b0060","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/ene.12329","article-title":"Risk of non-melanoma skin cancer in myasthenia patients treated with azathioprine","volume":"21","author":"Pedersen","year":"2014","journal-title":"Eur J Neurol"},{"issue":"1-2","key":"10.1016\/j.jocn.2021.03.015_b0065","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jns.2014.07.060","article-title":"Extrathymic malignancies in a defined cohort of patients with myasthenia gravis","volume":"346","author":"Basta","year":"2014","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jocn.2021.03.015_b0070","doi-asserted-by":"crossref","unstructured":"Gilhus, N.E., et al., Myasthenia gravis. Nature Reviews Disease Primers, 2019. 5(1): p. 30.","DOI":"10.1038\/s41572-019-0079-y"},{"issue":"6","key":"10.1016\/j.jocn.2021.03.015_b0075","first-page":"1778","article-title":"A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis","volume":"50","author":"Palace","year":"1998","journal-title":"Myasthenia Gravis Study Group. Neurology"},{"issue":"8","key":"10.1016\/j.jocn.2021.03.015_b0080","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1007\/s00415-009-5091-9","article-title":"Risk factors for tumor occurrence in patients with myasthenia gravis","volume":"256","author":"Citterio","year":"2009","journal-title":"J Neurol"},{"issue":"12","key":"10.1016\/j.jocn.2021.03.015_b0085","first-page":"1249","article-title":"Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years","volume":"96","author":"Rawoot","year":"2006","journal-title":"S Afr Med J"},{"issue":"1-2","key":"10.1016\/j.jocn.2021.03.015_b0090","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jns.2005.05.009","article-title":"Extrathymic malignancies in patients with myasthenia gravis","volume":"237","author":"Levin","year":"2005","journal-title":"J Neurol Sci"},{"issue":"6","key":"10.1016\/j.jocn.2021.03.015_b0095","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1111\/ene.12108","article-title":"Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark","volume":"20","author":"Pedersen","year":"2013","journal-title":"Eur J Neurol"},{"issue":"9701","key":"10.1016\/j.jocn.2021.03.015_b0100","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","article-title":"Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study","volume":"374","author":"Beaugerie","year":"2009","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.jocn.2021.03.015_b0105","doi-asserted-by":"crossref","unstructured":"Herrinton, L.J., et al., Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. The American journal of gastroenterology, 2011. 106(12): p. 2146-2153.","DOI":"10.1038\/ajg.2011.283"},{"issue":"17","key":"10.1016\/j.jocn.2021.03.015_b0110","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.jocn.2021.03.015_b0115","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.396","article-title":"Nonmelanoma skin cancer risk awareness in azathioprine-treated myasthenia gravis patients","volume":"5","author":"McGurgan","year":"2015","journal-title":"Brain Behav"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821001259?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586821001259?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T21:25:39Z","timestamp":1760822739000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586821001259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":23,"alternative-id":["S0967586821001259"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2021.03.015","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cancer occurrence following azathioprine treatment in myasthenia gravis patients: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2021.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}